Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

20121,184 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet

Volume 380, Issue 9856, pp. 1829-1839

Field-Weighted Citation Impact: 56.23